Alaunos Therapeutics

Alaunos Therapeutics logo
🇺🇸United States
Ownership
Public
Employees
1
Market Cap
$4.4M
Website
http://www.alaunos.com
Introduction

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The compa...

Clinical Trials
Related News

A Study of Palifosfamide Tris Plus Doxorubicin Versus Doxorubicin in Unresectable or Metastatic Soft-tissue Sarcoma

First Posted Date
2008-07-18
Last Posted Date
2014-01-30
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
67
Registration Number
NCT00718484

Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
Drug: ZIO-201-T and doxorubicin
First Posted Date
2008-02-06
Last Posted Date
2009-09-17
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
30
Registration Number
NCT00608803

Study of Oral Palifosfamide Tris in Solid Tumors

Phase 1
Suspended
Conditions
Advanced Cancer
Interventions
Drug: oral palifosfamide tris
First Posted Date
2008-02-06
Last Posted Date
2008-05-05
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
20
Registration Number
NCT00607711

Phase I Study of Indibulin in Patients With Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
47
Registration Number
NCT00591136

Phase I Study in Advanced Solid Tumors

Phase 1
Conditions
Solid Tumors
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
22
Registration Number
NCT00591292

A Phase I Trial of ZIO-101 in Solid Tumors

Phase 1
Completed
Conditions
Solid Tumors
Interventions
Drug: ZIO-101 (Darinaparsin)
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
40
Registration Number
NCT00591396

Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas

First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
20
Registration Number
NCT00592163

Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas

Phase 1
Conditions
Advanced Cancer
Interventions
Drug: ZIO-101-C (Darinaparsin)
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
23
Registration Number
NCT00591422

A Phase I Trial of ZIO-101 in Hematologic Cancers

First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
12
Registration Number
NCT00592046

Phase IB Study of Indibulin Using Positron-Emission Tomography (PET) Scans

Phase 1
Completed
Conditions
Advanced Cancer
Interventions
Drug: indibulin
First Posted Date
2008-01-11
Last Posted Date
2012-07-19
Lead Sponsor
Alaunos Therapeutics
Target Recruit Count
20
Registration Number
NCT00591890
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy